NEW YORK (360Dx) – Leo Pharma said today that it has entered a collaboration with Estonia-based FibroTx to assess disease severity and monitor treatment effects in atopic dermatitis patients using a non-invasive skin test technology developed by FibroTx.
FibroTx has developed two proprietary diagnostic platforms, Tap and Self, that enable measurements of panels of soluble biomarkers directly from the skin surface. FibroTx Tap is a non-invasive lateral flow ELISA platform that uses biomarker-capturing antibodies to detect proteins directly from the skin surface. FibroTx Self is a lateral flow-test platform in which samples swabbed from skin are analyzed in rapid tests that are read by a mobile phone or lateral flow test reader, depending on the application.
Per Sprøgel, vice president of medical science and safety at Denmark-based Leo Pharma, said in a statement that FibroTx's technology will help it measure therapeutic responses to its treatment. "It is especially important to seek less painful skin sampling in patients with already compromised skin,” he said.
According to a Leo Pharma spokesperson, the firm has several treatments in its pipeline targeting atopic dermatitis where the FibroTx diagnostic platforms "can be relevant." They include tralokinumab, an IL-13 antibody for systemic treatment of atopic dermatitis, and delgocitinib, a topical treatment for inflammatory skin diseases intended to provide an improved safety profile over topical steroids.
Pieter Spee, chief technology officer of FibroTx, said that the alliance with Leo Pharma marks "a major strengthening" of his firm's efforts "in the development of practical home tests that can improve treatment of atopic dermatitis patients.”
Further terms of the alliance were not disclosed.